🔗 Visit the ClinicalTrials.gov page for NCT01317641
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. | Lancet Oncol | 2014 | 3.44 |
| 2 | Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. | Oncogene | 2014 | 1.31 |
| 3 | Androgen receptor antagonists in castration-resistant prostate cancer. | Cancer J | 2013 | 1.19 |
| 4 | Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. | Int J Mol Sci | 2013 | 0.88 |